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Complement activation is integral to the development and
progression of multiple forms of kidney disease. The liver
is the principal source of serum complement, but various
kidney cell types and bone marrow–derived immune cells
can produce a full array of complement proteins. Locally
produced and activated complement yields cleavage
products that function as vital intermediaries, amplifying
inflammation in ischemia–reperfusion injury and transplant
rejection, among other pathological states. Additional
new studies indicate that during cognate T-cell–antigen
presenting cell interactions, both cell types produce
alternative pathway complement components. The resultant
activation products have an essential role in T-cell activation,
expansion, and differentiation, which in turn has a profound
impact on the development of immune-mediated kidney
disease. The recognition of an expanded role for kidney
cell–derived and immune cell–produced complement as
pathogenic to the kidney supports the need for future
studies to test the efficacy of complement inhibitors in the
prevention and/or treatment of selected kidney diseases.
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Serum complement, traditionally considered a component of
the innate immune system required for host defense against
invading pathogens, is an established mediator of various forms
of kidney disease. Over the last decade, a number of experi-
mental observations, including the fact that wild-type (WT)
mice with intact serum complement activity do not reject
C3-deficient kidney allografts,1 have provided new mechanistic
insights into the physiological and pathogenic effects of comple-
ment in vivo. These paradigm-shifting findings indicate that
tissue- and immune cell-derived complement, in addition to
serum complement, can exert profound effects on the develop-
ment of tissue inflammation, as well as on the strength and
cytokine profile of adaptive T-cell immune responses. In this
mini review, we summarize several of these observations with a
focus on proximal complement activation products (rather than
C6-9), describe how these novel mechanisms apply to kidney
disease, and provide a perspective on how they could ultimately
influence strategies aimed at preventing or treating kidney injury.
OVERVIEW OF THE COMPLEMENT CASCADE
Complement activation is initiated through classical, alternative,
or mannose-binding lectin pathways that converge at the
production of the C3 convertase, a central amplification step
within the cascade (Figure 1). Subsequent cleavage of C3 and
then of C5 initiates formation of the membrane attack complex
and yields soluble and surface-bound split products, including
C3a, C3b, iC3b, C3dg, and C5a, which serve as chemoattrac-
tants, activators of innate immune cells (for example, macro-
phages), and opsonins, among other functions (Figure 1).
The current concept is that complement activation must
be regulated to prevent bystander damage to host cells in vivo.
This regulation is accomplished through secretion and
expression of both soluble and membrane-bound comple-
ment regulatory proteins (Figure 1). Soluble regulatory
proteins include Factor H, which together with Factor I,
inactivates C3 convertases. Decay-accelerating factor (DAF or
CD55) is one of the several membrane-bound, complement
regulatory proteins, and its function is to accelerate the decay
of cell surface-assembled, C3 convertases (Figure 1). Dis-
association/inactivation of the C3 convertase limits amplifica-
tion of complement activation and as a consequence, restricts
production of the aforementioned cleavage products.2
SERUM COMPLEMENT AND KIDNEY DISEASE
Serum complement participates in the phenotypic expression
of diverse forms of kidney disease. The reader is referred
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elsewhere for a review of this topic, which includes how
antibody-initiated, classical pathway activation of serum
complement affects the pathogenesis of several glomerulone-
phritides.3 Serum complement activated through the classical
pathway is also the source of C4d deposits, characteristic of
antibody-mediated kidney transplant rejection (reviewed in
Nangaku and Couser3 and Collins et al.4). As another
example of how serum complement can contribute to renal
disease, loss-of-function mutations of Factor H (or mem-
brane cofactor protein, see Figure 1) can result in unregulated
serum, alternative pathway, complement activation, and
atypical forms of hemolytic uremic syndrome (reviewed in
Kavanagh et al.5).
Serum complement can also influence the strength of
adaptive humoral immunity,6 which could potentially
influence the phenotypic expression of autoantibody-
mediated kidney disease. The mechanism underlying this
effect involves the C3b cleavage product C3dg that binds to B
cell-expressed complement receptor 2 (CD21), facilitating
antigen presentation to B cells and lowering the threshold
for B-cell activation, together enhancing pathogen-specific
antibody production (reviewed in Carroll6).
KIDNEY-DERIVED COMPLEMENT IN THE PATHOGENESIS OF
RENAL DISEASE
Although traditional thinking focuses on the pathogenic
effects of liver-derived serum complement as a principal
pathogenic mediator of kidney injury, it is now abundantly
clear that complement components are produced by
parenchymal tissues other than the liver. The non-liver-
derived complement can be released and activated locally
under various circumstances. Evidence indicates that this
local production of complement can function as a ‘danger
signal’ to initiate and amplify kidney inflammation
and repair.
In groundbreaking studies that highlighted the impor-
tance of non-liver, tissue-derived complement production,
Sacks and colleagues1 demonstrated that WTmice with intact
serum complement activity do not reject allogeneic
C3-deficient kidneys. Mechanisms of this surprising observa-
tion include an effect of complement on the development of
pathogenic T-cell immunity (discussed below), and the fact
that kidney-derived complement is a key mediator of
ischemia–reperfusion (IR) injury.7,8
C3 is synthesized by tubular, mesangial, and endothelial
cells and is rapidly upregulated after IR.9 C3- or Factor
B-deficient mice are resistant to renal IR injury, underscoring
the key role for complement in this process.7,10 In contrast,
C4 deficiency is not protective, together indicating that
kidney IR injury requires complement activation through the
alternative pathway.7,10 In further support of a key role for
complement in this process are data that verify that post-
ischemic injury is exacerbated in animals deficient in the
complement regulator DAF (in which restraint on activation
of locally produced complement is lifted).8
Other studies show that murine C3-deficient kidneys are
protected from post-ischemic damage after transplantation
into syngeneic, murine recipients with normal serum
complement activity.7 WT (C3þ ) kidneys develop IR injury
upon transplantation into syngeneic C3-deficient recipients
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Figure 1 | Schematic overview of the complement cascade illustrating the three activation pathways (classical, mannose-binding
lectin (MBL), and alternative), the common pathway, the membrane attack complex (C5b-9), and the site of action of the cell
surface-expressed complement regulators (red) and the soluble complement regulator Factor H (blue). Representative functions
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(no serum C3). These data provide formal proof that kidney-
derived C3, not serum C3, drives the expression of IR injury
in this model.
Mechanistic analyses show that the complement-split
products C5a and C3a are important intermediaries in the
development of kidney IR injury. These cleavage products
bind in a paracrine manner to their receptors (C3aR and
C5aR) expressed on renal tubular, endothelial, and innate
immune cells (for example, neutrophils, macrophages). Signaling
through the 7-transmembrane spanning, G-protein-coupled
C5aR and C3aR stimulate upregulation and release of chemo-
kines, which facilitates and amplifies leukocyte infiltration into
the kidney, augments local inflammation through cytokine
production, and ultimately results in tissue injury and renal
dysfunction.8,11
Small interfering RNA-induced downregulation of the
C5aR12 or administration of a C5aR antagonist13 can
prevent/limit IR injury in rodents, supporting a pathogenic
role for C5a–C5aR interactions in the pathogenesis of this
disease.14 The previously described fact that an extravascular
pool of kidney-generated complement is pathogenic in kidney
IR injury further increased the possibility that blocking local
complement activation might be useful therapeutically. As proof
of this concept, overexpression of a molecularly engineered,
lipid-tailed, complement regulatory protein on kidney graft
endothelium limited the extent of IR injury after transplan-
tation.15 These novel insights and intriguing therapeutic
results support the notion that regulation or inhibition of
local (kidney-derived) complement activation could be useful
to prevent and possibly treat renal IR injury in humans.
Kidney-derived complement also affects other tubuloin-
terstitial diseases.1,7,8,16 C3-deficient kidneys are resistant to
adriamycin-induced tubular damage and progressive renal
failure, even when transplanted into recipients with normal
circulating complement activity.16 Addition of C3a to
cultured renal tubular cells decreases e-cadherin and
upregulates a-smooth muscle actin and type I collagen
production, consistent with an epithelial-to-mesenchymal
transition associated with progressive renal fibrosis.17 In
C3aR-deficient mice, adriamycin induces less injury with
lower expression of interstitial type 1 collagen and less
a-smooth muscle actin. Taken together, these data support
the view that local complement release and activation can
trigger acute kidney inflammation and, in select circum-
stances, participate in the development of chronic tubuloin-
terstitial injury in rodent models. The extent to which
complement activation contributes to the pathogenesis of
progressive kidney injury in humans is not known and will
require further investigation.
COMPLEMENT AND ADAPTIVE CELLULAR IMMUNITY
The recent insight that immune cells, including T cells and
antigen presenting cells (APCs), produce complement has
implications for transplantation and autoimmune disease
(Figure 2). This locally synthesized and activated complement
has a key physiological role in immune cell survival and function.
Studies by Heeger et al. and Medof et al.18–25 showed that
cognate T-cell–APC interactions that result in T-cell activa-
tion are associated with the upregulation and release of
alternative pathway complement components (C3, Factor B,
Factor D) by both cell types. Simultaneous with the induced
complement release, cell surface DAF expression is markedly
but transiently downregulated on both the T cell and the
APC, lifting restraint on activation of the locally released
complement (Figure 2). The resultant cleavage products, C3a
and C5a, bind to C3aR and C5aR, expressed on T cells, and
augment the strength of the induced T-cell response.24
Unexpectedly, this research group further documented that
complement release is a downstream consequence of
costimulatory signals transmitted by CD28/B7 and CD40/
CD40 ligand interactions, two ‘second signals’ that are
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Figure 2 | Schematic depiction of how complement modulates
T-cell immunity. Cognate T-cell–APC interactions result in the
upregulation and release of alternative pathway complement
components by both partners and in the downregulation of (a)
cell-surface DAF, which permits local complement activation
resulting in the production of (b) C3a and C5a. These split
products bind to their G-protein-coupled receptors expressed on
T cells, signaling through PI3Kg and AKT to induce proliferation
and inhibit apoptosis, while simultaneously activating APCs to
upregulate B7 and innate cytokine (for example, IL-12)
production. APC, antigen presenting cell; DAF, decay-accelerating
factor; IL-12, interleukin-12; PI3Kg, phosphoinositide 3-kinase-g.
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believed to be required for T-cell activation. In the absence
of C3aR and C5aR, T-cell–APC interactions do not result in
T-cell activation, despite the CD28/B7 ligation. Moreover,
addition of recombinant C5a augments T-cell proliferation
even in the absence of CD28/B7 signaling. Taken together,
these findings indicate that C3aR/C5aR-transmitted
signals are requisite downstream components underlying
costimulation.24
Further evidence that complement physiologically reg-
ulates T cells is derived from experiments showing that the
ligation of C3a–C3aR and C5a–C5aR interactions is bio-
chemically linked to known intracellular signaling pathways
involved in T-cell activation (Figure 2).20,24 C5aR and C3aR
signaling in T cells activates phosphoinositide 3-kinase-g,
and induces phosphorylation of the central intracellular
signaling molecule AKT. Phosphorylation of AKTupregulates
the anti-apoptotic gene Bcl2 and downregulates surface
expression of the proapoptotic molecule Fas.20 Taken
together, these effects enhance T-cell proliferation and
diminish T-cell apoptosis, explaining the complement-
mediated expansion of the effector T-cell repertoire after
antigenic stimulation. Intriguingly, the evidence also indi-
cates that C3aR and C5aR signaling is required for
T-cell homeostasis, as T cells deficient in both receptors
spontaneously undergo accelerated cell death in vitro and
in vivo.24
The immune cell-derived and locally produced C3a and
C5a also bind to C3aR/C5aR on APCs (including dendritic
cells and macrophages, Figure 2). C5aR/C3aR ligation activates
APCs, inducing the release of innate cytokines (for example,
interleukin-12, interleukin-23) and upregulating APC costimu-
latory molecules (for example, B7), further amplifying the
immune response and modulating the phenotype toward
interferon-g-producing Th1 immunity.8,18–25 Importantly,
in vivo studies conducted using bone marrow chimeric
animals demonstrated that all of these effects on T-cell
immunity are mediated by immune cell-derived complement
and are independent of serum complement.19,20,22
Complement-dependent effects on alloreactive T-cell
immunity regulate the phenotypic expression of immune-
mediated injury in animal models. In addition to the
aforementioned observation that WT mice do not reject
allogeneic C3-deficient kidneys,1 WT mice reject DAF-
deficient heart allografts (enhances local complement activa-
tion) with accelerated kinetics compared with WT grafts.22
The accelerated rejection of DAF-deficient heart transplants
is associated with augmented anti-donor T-cell reactivity and
is notable in animals devoid of B cells, confirming that local
complement activation accelerates graft rejection through
a T cell-dependent mechanism. Additional data show that
immune cell-derived and donor graft-derived complement,
but not serum complement, regulate expansion of both
alloreactive CD4þ and CD8þ T cells.22,23 Endothelial
cell-driven expansion of alloreactive T cells in vitro and in
vivo is also regulated by the locally produced complement
(produced by both T cells and endothelial cells).23
Further confirming a key role for C5a–C5aR interactions
as pathogenic in transplant rejection are data indicating that
C5aR blockade prolongs kidney transplant survival in
rodents.14 This improved outcome is associated with an
abrogation of intragraft mononuclear cell infiltration and a
diminution in T-cell alloreactivity.14 Taken together, these
results indicate that complement is a physiologically
important regulator of alloreactive T-cell immunity. The
findings support the need for testing complement blockade
as an adjunctive therapeutic approach to prolong transplant
survival in humans.
The effects of immune cell-derived complement extend
beyond transplantation. In this regard, complement posi-
tively regulates antiviral immunity and autoimmunity in
rodent models. Experimental allergic encephalomyelitis is
one model of T cell-mediated autoimmunity that mimics
aspects of human multiple sclerosis.21,24 DAF-deficient mice
develop more severe experimental allergic encephalomyelitis
than do WT animals, and the phenotype is associated with
stronger autoreactive T-cell immunity. These effects on
T cells are C5aR- and C3aR-dependent, as mice deficient in
either or both of these receptors develop less autoimmunity
and are resistant to experimental allergic encephalomyelitis,
regardless of DAF expression.24
In separate work directly relevant to the pathogenesis of
autoimmune renal disease, Bao et al.26 described a new
model of focal and segmental glomerulosclerosis in DAF
knockout mice. In this model, focal and segmental
glomerulosclerosis was caused by enhanced T-cell immunity
as a result of the absence of DAF on T cells, and was not a
direct or indirect effect of complement on antibody-initiated
glomerular injury. These combined data obtained from
numerous disease models verify that the regulation of
T-cell responses by immune cell-derived complement can
have important pathophysiological consequences.
RELEVANCE TO HUMAN DISEASE
Selected studies have suggested that immune cell-derived
and/or graft-derived complement contributes to human
transplant rejection. The quantity of RNA message for
alternative pathway complement components and comple-
ment receptors, including C5aR and C3aR, is higher in
human transplant tissue with histological evidence of
rejection compared with non-injured control tissue.14,27
Gene expression profiling of human kidney transplants
reveals higher expression of several complement genes in
deceased donor grafts with longer ischemic times, and
interestingly, the complement gene upregulation correlates
inversely with early and late renal function.28 In another
intriguing report, donor kidney expression of a specific
polymorphic variant of C3 is associated with worse
posttransplantion outcomes.29 The precise mechanism
through which this mutation alters allograft injury in human
transplant recipients remains unclear, and an independent
study of a disparate and larger patient population could not
verify these initial findings.30
498 Kidney International (2010) 77, 495–499
min i rev iew M Vieyra and PS Heeger: Complement and kidney injury
CONCLUSIONS
Although the complement system was originally discovered as
a serum component that ‘complemented’ antibodies in the
killing of bacteria, it is clear that complement has a multitude
of other functions. The complexities of the contributions of the
complement to kidney disease extend beyond the established
role of the membrane attack complex as a mediator of
glomerulonephritis. One must understand the various activa-
tion pathways (such as classical pathway activation in antibody-
mediated injury, alternative pathway activation as pathogenic
in kidney IR injury), and comprehend the expression and
function of complement regulatory proteins (for example,
Factor H mutations and hemolytic uremic syndrome) and the
source of the complement (serum or non-liver derived).
Emerging data indicate that in response to injury, kidney-
derived complement can function as a danger signal that initiates
inflammation and repair, and if left unchecked can contribute to
the development of chronic organ damage. Local complement
activation also physiologically regulates immune cell survival and
proliferation, modulating the strength and phenotype of
adaptive T-cell immune responses involved in autoimmune
glomerular disease and alloimmune transplant rejection.
Consideration of the cellular source and local function of
complement has potential therapeutic implications. Anti-
bodies capable of blocking complement activation, including
an anti-C5 antibody approved for use in humans with
paroxysmal nocturnal hemoglobinuria,31 may be most
beneficial as inhibitors of circulating serum complement
(for example, decreasing posttransplant graft injury caused
by alloantibody-initiated complement activation). Small
molecule receptor inhibitors, which are in development for
human use, may better penetrate tissues to restrain down-
stream consequences of the released cleavage products (for
example, C3a and C5a), and thereby restrain the influence of
complement over immune cells or the kidney parenchyma.
Local treatment of donor organs with cell surface-expressed
complement inhibitors to prevent delayed graft function post
transplant represents one approach15 that could theoretically
benefit transplant recipients without the requirement for
systemic drug administration. The recognition of the
diversity through which complement participates in renal
injury supports the need for continued design and testing of
complement inhibitors in the clinic.
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